Research
Hormonal
Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.
Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.
StrongSupportsmedium confidence
From baseline to week 52, the least square (LS) mean predicted T2D risk changed from 5.3% to 1.2% for tirzepatide 10 mg.
Why this rating
Based on the randomized controlled trial design of the SURMOUNT-CN trial.
Source
Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trial
Lin Zhao et al. · Diabetes Obesity and Metabolism · 2025
other · n=169Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →